Global Search

Hide Filters

Showing 1136 results

Press release / Dec 16, 2016

Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes

Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
Press release / Apr 26, 2017

Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma

Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be…
Press release / Oct 05, 2015

Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery

AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…
Press release / Oct 23, 2020

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases IgA nephropathy (IgAN), while rare, is the most common form of…
Press release / Jun 17, 2017

Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease

Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-…
Press release / Sep 12, 2017

Sandoz proposed biosimilar rituximab accepted for review by the FDA

Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms…
Press release / Sep 06, 2019

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy…
Press release / Jul 01, 2019

Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed

Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
Press release / Jun 14, 2019

New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
Press release / Mar 18, 2019

Alcon Announces Acquisition of PowerVision, Inc.

Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…

‹ Previous page
1
…
64
65
66
67
68
69
70
…
114
› Next page